The treatment targets certain types of solid tumors that show rare genetic defects called NTRK gene fusions.
The treatment works regardless of where the tumor started in the body, according to a news release.
This is the third oncology drug that targets a key genetic driver of cancer rather than a specific type of tumor.
More articles on pharmacy:
CMS to cover CAR-T therapy nationwide
Colombia fines Pfizer $25K for drug price inflation
Jefferson Healthcare opens retail specialty pharmacy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.